Loading...

Purified anti-mouse CD11c Antibody

Pricing & Availability
Clone
N418 (See other available formats)
Regulatory Status
RUO
Other Names
αX integrin, integrin αX chain, CR4, p150, ITGAX
Isotype
Armenian Hamster IgG
Ave. Rating
Submit a Review
Product Citations
publications
N418_A_Purified_Pos_071006.jpg
C57BL/6 mouse splenocytes stained with APC anti-mouse I-A/I-E (clone M5/114.15.2) and purified N418 (top) or purified Armenian hamster IgG isotype control (bottom), followed by anti-Armenian hamster IgG FITC
  • N418_A_Purified_Pos_071006.jpg
    C57BL/6 mouse splenocytes stained with APC anti-mouse I-A/I-E (clone M5/114.15.2) and purified N418 (top) or purified Armenian hamster IgG isotype control (bottom), followed by anti-Armenian hamster IgG FITC
  • N418_B_Purified_Neg_071006.jpg
Compare all formats
Cat # Size Price Quantity Check Availability Save
117301 50 µg 36 CHF
Check Availability


Need larger quantities of this item?
Request Bulk Quote
117302 500 µg 141 CHF
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

CD11c is a 150 kD glycoprotein also known as αX integrin, CR4, and p150. CD11c forms a αXβ2 heterodimer with β2 integrin (CD18). It is primarily expressed on dendritic cells, NK cells, a subset of intestinal intraepithelial lymphocytes (IEL), and some activated T cells. The αXβ2 integrin plays an important role in cell-cell contact by binding its ligands: iC3b, fibrinogen, and CD54.

Product Details
Technical Data Sheet (pdf)

Product Details

Verified Reactivity
Mouse
Antibody Type
Monoclonal
Host Species
Armenian Hamster
Immunogen
Mouse spleen dendritic cells
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation
The antibody was purified by affinity chromatography.
Concentration
0.5 mg/ml
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C.
Application

FC - Quality tested
CyTOF® - Verified
IP, IHC - Reported in the literature, not verified in house
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤1.0 µg per million cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.

Application Notes

Additional reported applications (for the relevant formats) include: immunoprecipitation3, immunohistochemical staining of acetone-fixed frozen sections3, immunofluorescence microscopy5, 9 (Alexa Fluor® 488 conjugated N418 was used for IHC in frozen sections10), and spatial biology (IBEX)22,23.

Application References

(PubMed link indicates BioLegend citation)
  1. Granucci F, et al. 1997. J. Immunol. 159:1794.
  2. Stokes RW, et al. 1998. J. Immunol. 160:5514.
  3. Metlay JP, et al. 1990. J. Exp. Med. 171:1753. (IHC, IP)
  4. Ma XT, et al. 2006. Cancer Research 66:1169.
  5. Chin RK, et al. 2006. J. Immunol. 177:290. (IF)
  6. Cervantes-Barragan L, et al. 2007. Blood 109:1131. (FC) PubMed
  7. Turnquist HR, et al. 2007. J. Immunol. 178:7018. (FC) PubMed
  8. Benson MJ, et al. 2007. J. Exp. Med. doi:10.1084/jem.20070719. (FC) PubMed
  9. You Y, et al. 2009. J. Immunol. 182:7343. (IF) PubMed
  10. Roland CL, et al. 2009. Mol. Cancer Res. 8:1761. (IHC, FC) PubMed
  11. Wikstrom M, et al.2006. J. Immunol. 177:913. PubMed
  12. Pericolini E, et al. 2008. J. Leukocyte Biol. 83:1286. PubMed
  13. Randall LM, et al. 2008. Infect. Immun.76:3312. PubMed
  14. Fahlen-Yrild L, et al. 2009. J. Immunol. 183:5032. PubMed
  15. Osterholzer JJ, et al. 2009. J. Immunol. 183:8044. PubMed
  16. Bankoti J, et al. 2010. Toxicol. Sci. 115:422. (FC) PubMed
  17. Eisenach PA, et al. 2010. J Cell Sci. 123:4182. PubMed
  18. Leppin K, et al. 2014. Invest. Ophthalmol. Vis. Sci. 55:3603. PubMed
  19. Sakai F, et al. 2014. PLoS One. 9:105370. PubMed
  20. Gibbins JD, et al. 2014. Blood. 124:2953. PubMed
  21. White CE, et al. 2015. J Immunol. 194:697. PubMed
  22. Lu X, et al. 2015. J Immunol. 194:2011. PubMed
  23. Radtke AJ, et al. 2020. Proc Natl Acad Sci U S A. 117:33455-65. (SB) PubMed
  24. Radtke AJ, et al. 2022. Nat Protoc. 17:378-401. (SB) PubMed
Product Citations
  1. Hutton C, et al. 2021. Cancer Cell. 39:1227. PubMed
  2. Aguilar EG, et al. 2021. Blood Adv. 5:4219. PubMed
  3. Owen KL, et al. 2020. EMBO Rep. 21:e50162. PubMed
  4. Kobayashi A, et al. 2021. Front Immunol. 12:650856. PubMed
  5. Paterson MJ, et al. 2020. PLoS Pathog. 16:e1008733. PubMed
  6. Bruce DW, et al. 2021. Blood Adv. 5:4578. PubMed
  7. Li F, et al. 2020. EMBO J. 39:e103205. PubMed
  8. Liu CJ, et al. 2020. Neuro Oncol. 22:1276. PubMed
  9. Doll JR, et al. 2020. PLoS Pathog. 16:e1008296. PubMed
  10. Blériot C, et al. 2020. Methods Mol Biol. 2164:87. PubMed
  11. Cai S, et al. 2020. Sci Rep. 10:14249. PubMed
  12. Malinczak CA, et al. 2021. J Immunol. 206:1315. PubMed
  13. Li H, et al. 2022. Cancer Cell. 40:36. PubMed
  14. Valet C, et al. 2022. J Clin Invest. 132: . PubMed
  15. Liedmann S, et al. 2022. Mol Cell. 82:2401. PubMed
  16. Campisi L, et al. 2022. Nature. 606:945. PubMed
  17. Chi H, et al. 2022. Cells. 11: . PubMed
  18. Moore AR, et al. 2022. Cell Rep. 41:111651. PubMed
  19. Jiang L, et al. 2021. Nano Today. 36:. PubMed
  20. Hezaveh K, et al. 2022. Immunity. 55:324. PubMed
  21. Chen W, et al. 2023. JCI Insight. 8:. PubMed
  22. Iguchi A, et al. 2023. iScience. 26:106375. PubMed
  23. Xu J, et al. 2023. Discov Oncol. 14:68. PubMed
  24. Hernández-Santana YE, et al. 2020. Life Sci Alliance. 3:00. PubMed
  25. Martinez LE, et al. 2020. J Virol. 94:00:00. PubMed
  26. Dallari S, et al. 2017. Nat Commun. 8:14830. PubMed
  27. Arnold IC, et al. 2019. PLoS Pathog. 15:e1007866. PubMed
  28. Bajaña S, et al. 2021. Front Immunol. 11:577718. PubMed
  29. Wan Mohd Zawawi WFA, et al. 2021. Sci Rep. 11:10278. PubMed
  30. Khan KA, et al. 2020. NPJ Breast Cancer. 6:29. PubMed
  31. Mendes A, et al. 2021. Life Sci Alliance. 4:00. PubMed
  32. Fahlén-Yrlid L, et al. 2009. J Immunol. 183:5032. PubMed
  33. Osterholzer J, et al. 2009. J Immunol. 183:8044. PubMed
  34. Sun L, et al. 2020. Nat Commun. 2.229166667. PubMed
  35. Trittel S, et al. 2019. Sci Rep. 9:16362. PubMed
  36. Mazor R, et al. 2018. Proc Natl Acad Sci U S A. 115:E733. PubMed
  37. Bhatt K, et al. 2018. mSphere. 3:e00352. PubMed
  38. Chartrand K, et al. 2018. Front Immunol. 1.642361111. PubMed
  39. Prado C, et al. 2021. J Neuroinflammation. 18:292. PubMed
  40. Bachran C, et al. 2017. Sci Rep.. 10.1038/s41598-017-17948-0. PubMed
  41. Rieck M, et al. 2017. Eur J Immunol. 47:677. PubMed
  42. Dubrot J, et al. 2018. Life Sci Alliance. 1:e201800164. PubMed
  43. Field CS, et al. 2018. Oncoimmunology. 7:e1376154. PubMed
  44. Wang W, et al. 2018. Cancer Cell. 34:757. PubMed
  45. Arnold IC, et al. 2018. J Exp Med. 215:2055. PubMed
  46. Mayer JU, et al. 2020. Front Immunol. 11:592325. PubMed
  47. Fang C, et al. 2020. Cell Mol Immunol. . PubMed
  48. Bonnefoy F, et al. 2018. Front Immunol. 2.170833333. PubMed
  49. Cao Q, et al. 2018. Am J Physiol Renal Physiol. 314:F561. PubMed
  50. Periasamy S, et al. 2017. Nat Commun. 8:15564. PubMed
  51. Lechner AJ et al. 2017. Cell stem cell. 21(1):120-134 . PubMed
  52. Lee JH, et al. 2022. iScience. 25:104166. PubMed
  53. Jackson JW, et al. 2021. Mol Ther Oncolytics. 22:444. PubMed
  54. Mayer KA, et al. 2021. FASEB J. 35:e21217. PubMed
  55. Delgobo M, et al. 2021. Front Immunol. 12:584538. PubMed
  56. Peng V, et al. 2020. J Biol Chem. 295:14866. PubMed
  57. Tal MC, et al. 2020. MBio. 11:00. PubMed
  58. Hitchcock JR, et al. 2020. FEBS J. 287:250. PubMed
  59. McLeod RL, et al. 2018. Oncotarget. 9:34459. PubMed
  60. Kitai Y, et al. 2017. J Immunol. 198:1649. PubMed
  61. Sutton C, et al. 2017. Nat Commun.. 10.1038/s41467-017-02111-0. PubMed
  62. Hilligan KL, et al. 2020. Nat Commun. 11:5637. PubMed
  63. Suzuki Y, et al. 2021. FEBS Open Bio. 11:2619. PubMed
  64. Yan J, et al. 2020. Cancer Immunol Res. 8:356. PubMed
  65. Chen L, et al. 2020. Front Immunol. 11:584458. PubMed
  66. Aparicio-Domingo P, et al. 2015. J Exp Med. 101084/jm20150318. PubMed
  67. Shimokawa C et al. 2017. Immunity. 46(5):863-874 . PubMed
  68. Nolin JD, et al. 2017. JCI Insight. 2:e94929. PubMed
  69. Sun H, et al. 2018. J Cell Biol. 217:1453. PubMed
  70. Chen S, et al. 2018. Immunohorizons. 0.345138889. PubMed
  71. Khan KA, et al. 2020. NPJ Breast Cancer. 6:29. PubMed
  72. He LD, et al. 2021. EMBO Rep. 22:e52196. PubMed
  73. Sun Y, et al. 2022. Nat Commun. 13:3916. PubMed
  74. Manni M, et al. 2018. Nat Immunol. 1.074305556. PubMed
  75. Stacey MA, et al. 2017. J Clin Invest. 127:1463. PubMed
  76. Fu H, et al. 2019. Front Immunol. 10:271. PubMed
  77. Snell LM, et al. 2018. Immunity. 49:678. PubMed
  78. Mrdjen D et al. 2018. Immunity. 48(2):380-395 . PubMed
  79. Lai JF, et al. 2020. J Allergy Clin Immunol. 146:1406. PubMed
  80. Liu H, et al. 2020. J Immunol. 205:1207. PubMed
  81. Wang Y, et al. 2021. Sci Transl Med. 13:. PubMed
  82. Brown IK, et al. 2021. PLoS Pathog. 17:e1009602. PubMed
  83. Molica F,et al. 2017. Sci Rep.. 10.1038/s41598-017-14130-4. PubMed
  84. Gartlan KH, et al. 2019. Blood Adv. 2.110416667. PubMed
  85. Mainini F, et al. 2018. Nucleic Acid Ther. 28:225. PubMed
  86. Enders M, et al. 2020. J Immunol. 204:87. PubMed
  87. Wei S, et al. 2019. Virulence. 0.588888889. PubMed
  88. Tsubaki T, et al. 2018. Oncotarget. 9:11209. PubMed
  89. Borges TJ, et al. 2018. Nat Commun. 9:3482. PubMed
  90. Johnson SA, et al. 2021. Eur J Immunol. 51:3228. PubMed
  91. Schuler CF, et al. 2020. Allergy. 75:2279. PubMed
  92. Lim CS, et al. 2020. Front Immunol. 11:1186. PubMed
  93. Tao H, et al. 2021. Front Immunol. 12:623280. PubMed
  94. Lee JY, et al. 2018. Front Immunol. 0.678472222. PubMed
  95. Nascimento DC, et al. 2017. Nat Commun. 8:14919. PubMed
  96. Shin J, et al. 2018. Diabetes. 67:1068. PubMed
  97. Majer O, et al. 2019. Nature. 575:366. PubMed
  98. Pericolini E, et al. 2008. J Leukoc Biol. 83:1286. PubMed
  99. Guilliams M, et al. 2022. Cell. 185:379. PubMed
  100. Chen HW, et al. 2021. Biomedicines. 9:. PubMed
  101. Blriot C, et al. 2021. Immunity. :. PubMed
  102. Murakami R, et al. 2013. PLoS One. 8:73270. PubMed
  103. Matsuo K, et al. 2018. J Invest Dermatol. 138:1764. PubMed
  104. King IL, et al. 2017. Mucosal Immunol. 10:1160. PubMed
  105. Denny JE, et al. 2019. Sci Rep. 2.786111111. PubMed
  106. Nagatake T, et al. 2018. Int Immunol. 30:471. PubMed
  107. Oyarce K, et al. 2018. Front Immunol. 9:112. PubMed
  108. Rebouças A, et al. 2021. Microorganisms. 9:. PubMed
  109. Rigo MM, et al. 2020. FEBS J. :. PubMed
  110. Li J, et al. 2021. Front Immunol. 12:710406. PubMed
  111. Cepeda JR, et al. 2020. MAbs. 12:1836714. PubMed
  112. Penkert RR, et al. 2020. Obesity (Silver Spring). 1631:28. PubMed
  113. Zhang Z, et al. 2018. Nat Med. 24:617. PubMed
  114. Parigi SM, et al. 2018. Sci Rep. 0.440277778. PubMed
  115. Hoffmann FM, et al. 2018. Front Immunol. 9:1046. PubMed
  116. Seo SU, et al. 2021. Front Immunol. 12:697162. PubMed
  117. Wikstrom M, et al. 2006. J Immunol. 177:913. PubMed
  118. Kim D, et al. 2019. Immune Netw. 19:e32. PubMed
  119. Kawabe T, et al. 2017. Sci Immunol. 2:eaam9315. PubMed
  120. Dahlgren MW et al. 2019. Immunity. 50(3):707-722 . PubMed
  121. Nagatake T, et al. 2018. J Allergy Clin Immunol. 142:470. PubMed
  122. Scortegagna M, et al. 2020. Nat Commun. 11:99. PubMed
  123. Brownlie D, et al. 2021. J Immunother Cancer. 9:. PubMed
  124. Calderon B, et al. 2015. J Exp Med. 212: 1497-1512. PubMed
  125. Keerthivasan S, et al. 2021. Immunity. 54(7):1511-1526.e8. PubMed
  126. Hammer A, et al. 2017. Front Immunol. . 10.3389/fimmu.2017.01922. PubMed
  127. Akiel M, et al. 2017. Cancer Res. 77:4014. PubMed
  128. von Roemeling CA, et al. 2020. Nat Commun. 11:1508. PubMed
  129. Cá B, et al. 2019. Front Microbiol. 1.876388889. PubMed
  130. Eisenach P, et al. 2010. J Cell Sci. 123:4182. PubMed
  131. Van Der Zande HJP, et al. 2021. FASEB J. 35:e21331. PubMed
  132. García G, et al. 2020. Am J Pathol. 844:190. PubMed
  133. Leppin K, et al. 2014. Invest Ophthalmol Vis Sci . 55:3603. PubMed
  134. Benson M, et al. 2007. J Exp Med. 204:1765. PubMed
  135. Simmons S et al. 2019. Elife. 8 pii: e41239. PubMed
  136. Fitzpatrick Z, et al. 2020. Nature. 587:472. PubMed
  137. Xu W, et al. 2021. Immunity. 54(3):526-541.e7. PubMed
  138. Goltsev Y et al. 2018. Cell. 174(4):968-981 . PubMed
  139. Satoh–Takayama N, et al. 2020. Immunity. 52(4):635-649. PubMed
  140. Chen B, et al. 2021. Cell. 184:6262. PubMed
  141. Pushalkar S, et al. 2018. Cancer Discov. 0.613194444. PubMed
  142. Danne C et al. 2017. Cell host & microbe. 22(6):733-745 . PubMed
  143. Song M, et al. 2020. Nat Commun. 11:6298. PubMed
  144. An Y et al. 2018. Cell reports. 25(3):702-714 . PubMed
  145. Hung LY, et al. 2019. J Immunol. 203:511. PubMed
  146. Rios–Doria J, et al. 2017. Cancer Res. 77:2686. PubMed
  147. Kikuchi K, et al. 2018. J Immunol. 201:635. PubMed
  148. Khameneh HJ, et al. 2017. J Immunol. 198:196. PubMed
  149. Kästele V, et al. 2021. Mucosal Immunol. 14:717. PubMed
  150. Prabakaran T, et al. 2021. EBioMedicine. 66:103314. PubMed
  151. Fritz Y, et al. 2017. J Invest Dermatol. 137:696. PubMed
  152. Ito Y, et al. 2018. J Exp Med. 215:2617. PubMed
RRID
AB_313770 (BioLegend Cat. No. 117301)
AB_313771 (BioLegend Cat. No. 117302)

Antigen Details

Structure
Integrin α-chain, associates with integrin β2 (CD18), 150 kD
Distribution

Dendritic cells, NK cells, intestinal intraepithelial lymphocytes (IEL), some activated T cells

Function
Cellular adhesion
Ligand/Receptor
iC3b, fibrinogen
Cell Type
Dendritic cells, Epithelial cells, NK cells, T cells, Tregs
Biology Area
Cell Adhesion, Cell Biology, Costimulatory Molecules, Immunology, Innate Immunity, Neuroscience, Neuroscience Cell Markers
Molecular Family
Adhesion Molecules, CD Molecules
Antigen References

1. Barclay A, et al. 1997. The Leukocyte Antigen Facts Book Academic Press.
2. Springer TA. 1994. Cell 76:301.
3. Lopez-Rodriguez C, et al. 1996. J. Immunol. 156:3780.

Gene ID
16411 View all products for this Gene ID
Specificity (DOES NOT SHOW ON TDS):
CD11c
Specificity Alt (DOES NOT SHOW ON TDS):
CD11c
App Abbreviation (DOES NOT SHOW ON TDS):
FC,CyTOF®,IP,IHC
UniProt
View information about CD11c on UniProt.org

Related FAQs

There are no FAQs for this product.

Other Formats

View All CD11c Reagents Request Custom Conjugation
Description Clone Applications
APC anti-mouse CD11c N418 FC
Biotin anti-mouse CD11c N418 FC,IHC-F
FITC anti-mouse CD11c N418 FC
PE anti-mouse CD11c N418 FC
Purified anti-mouse CD11c N418 FC,CyTOF®,IP,IHC
Alexa Fluor® 488 anti-mouse CD11c N418 FC
Alexa Fluor® 647 anti-mouse CD11c N418 FC,IHC,ICC,3D IHC
PE/Cyanine5 anti-mouse CD11c N418 FC
PE/Cyanine7 anti-mouse CD11c N418 FC
Brilliant Violet 605™ anti-mouse CD11c N418 FC
Alexa Fluor® 700 anti-mouse CD11c N418 FC
Pacific Blue™ anti-mouse CD11c N418 FC
APC/Cyanine7 anti-mouse CD11c N418 FC
PerCP/Cyanine5.5 anti-mouse CD11c N418 FC
PerCP anti-mouse CD11c N418 FC
Brilliant Violet 421™ anti-mouse CD11c N418 FC,IHC
Brilliant Violet 570™ anti-mouse CD11c N418 FC
Brilliant Violet 785™ anti-mouse CD11c N418 FC
Brilliant Violet 510™ anti-mouse CD11c N418 FC
Brilliant Violet 650™ anti-mouse CD11c N418 FC
Purified anti-mouse CD11c (Maxpar® Ready) N418 FC,CyTOF®
Alexa Fluor® 594 anti-mouse CD11c N418 IHC-F,3D IHC
PE/Dazzle™ 594 anti-mouse CD11c N418 FC
Brilliant Violet 711™ anti-mouse CD11c N418 FC
APC/Fire™ 750 anti-mouse CD11c N418 FC
TotalSeq™-A0106 anti-mouse CD11c N418 PG
Brilliant Violet 750™ anti-mouse CD11c N418 FC
TotalSeq™-B0106 anti-mouse CD11c N418 PG
TotalSeq™-C0106 anti-mouse CD11c N418 PG
KIRAVIA Blue 520™ anti-mouse CD11c N418 FC
Spark Blue™ 550 anti-mouse CD11c N418 FC
Spark NIR™ 685 anti-mouse CD11c N418 FC
Spark UV™ 387 anti-mouse CD11c N418 FC
Spark Red™ 718 anti-mouse CD11c N418 FC
Spark Blue™ 515 anti-mouse CD11c N418 FC
PerCP/Fire™ 806 anti-mouse CD11c N418 FC
Spark PLUS UV™ 395 anti-mouse CD11c N418 FC
Go To Top Version: 1    Revision Date: 11.30.2012

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere
Login / Register
Remember me
Forgot your password? Reset password?
Create an Account